<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076021</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002324</org_study_id>
    <secondary_id>R01GM124264</secondary_id>
    <nct_id>NCT03076021</nct_id>
  </id_info>
  <brief_title>Effects of Isotretinoin on CYP2D6 Activity</brief_title>
  <official_title>Effects of Isotretinoin on CYP2D6 Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases&#xD;
      CYP2D6 activity in adolescent patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this aim, we will conduct a drug-drug interaction study evaluating the effects of&#xD;
      13-cis-retinoic acid on non-induced CYP2D6 activity in adolescent patients. Secondary&#xD;
      analysis will evaluate the relationship between retinoid concentrations and CYP2D6 activity&#xD;
      in these special populations&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 26, 2016</start_date>
  <completion_date type="Anticipated">July 26, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, pre-post drug interaction study evaluating an approved drug (Phase 4) with a Phase 1 study design.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CYP2D6 activity</measure>
    <time_frame>1 week to 6 months</time_frame>
    <description>DM/DX Metabolic Ratio</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CYP2D6 Polymorphism</condition>
  <arm_group>
    <arm_group_label>Adolescents</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>dextromethorphan pre- and post isotretinoin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Drug interaction study</description>
    <arm_group_label>Adolescents</arm_group_label>
    <other_name>accutane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan</intervention_name>
    <description>Drug interaction study</description>
    <arm_group_label>Adolescents</arm_group_label>
    <other_name>robitussin pediatric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant&#xD;
&#xD;
          -  ≥ 12 years&#xD;
&#xD;
          -  Patients with severe acne that are expected to receive isotretinoin for therapeutic&#xD;
             reasons&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight &lt; 80 lbs&#xD;
&#xD;
          -  Allergy or adverse reaction to dextromethorphan, vitamin A or isotretinoin&#xD;
&#xD;
          -  Pregnant or planning to become pregnant&#xD;
&#xD;
          -  Unable to follow isotretinoin risk evaluation and mitigation strategies (REMS) program&#xD;
             (also known as iPLEDGE program)&#xD;
&#xD;
          -  Chronic or persistent cough accompanying asthma, smoking or COPD,&#xD;
&#xD;
          -  Productive cough,&#xD;
&#xD;
          -  Fever,&#xD;
&#xD;
          -  Known kidney disease,&#xD;
&#xD;
          -  Known liver disease,&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Obesity, BMI ≥ 30 kg/m2&#xD;
&#xD;
          -  Bipolar disease,&#xD;
&#xD;
          -  Attention deficit disorder,&#xD;
&#xD;
          -  Social phobia,&#xD;
&#xD;
          -  Concurrent or use within 14 days of drugs known to interact with DM or CYP2D6 or drugs&#xD;
             known to increase the risk of adverse effects from DM&#xD;
&#xD;
          -  Concurrent use of any other product containing dextromethorphan&#xD;
&#xD;
          -  Consuming foods, beverages or dietary supplements known to interact with DM or CYP2D6&#xD;
&#xD;
          -  Unable to give written informed consent/assent,&#xD;
&#xD;
          -  Inability to fast for 4 hours prior to study.&#xD;
&#xD;
          -  Wards of the State&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F Hebert, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Mary Hebert</investigator_full_name>
    <investigator_title>Professor of Pharmacy, Adjunct Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After completion of the study, we plan to follow NIGMS/NIH and University of Washington requirements for data sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

